(7) INVENTORY

Inventory consisted of the following:

		000000000000		000000000000
	September 30, 2011		December 31, 2010
Raw materials	$	15,267	$	11,174
Work-in-process		58,541		65,336
Finished goods		41,820		33,188

Total inventory	$	115,628	$	109,698

Inventory as of September 30, 2011 and December 31, 2010 includes $12.6 million and $14.8 million, respectively, of Naglazyme product manufactured in the Company's recently expanded production facility. The Company's expansion of its manufacturing facility, as for any new manufacturing facility or process, is required to be approved by the U.S. Food and Drug Administration (FDA) and similar ex-U.S. regulatory agencies before the product manufactured in this facility can be sold commercially. As of September 30, 2011, the expanded facility and new process have not been approved by the FDA or any other regulatory agency; however, the Company expects to receive FDA approval in the fourth quarter of 2011 or early 2012 and realize the costs of the remaining Naglazyme pre-qualification inventories through future sales.